Literature DB >> 28447911

Is There a Role for Ovarian Cancer Screening in High-Risk Women?

Andrew Berchuck1, Laura J Havrilesky1, Noah D Kauff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28447911     DOI： 10.1200/JCO.2016.72.0045

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.

Authors:  Sarah Knerr; Boya Guo; Kathleen F Mittendorf; Heather Spencer Feigelson; Marian J Gilmore; Gail P Jarvik; Tia L Kauffman; Erin Keast; Frances L Lynch; Kristin R Muessig; Sonia Okuyama; David L Veenstra; Jamilyn M Zepp; Katrina A B Goddard; Beth Devine
Journal:  Cancer       Date:  2022-06-09       Impact factor: 6.921

2.  Cancer screening in women living with HIV infection.

Authors:  David M Aboulafia
Journal:  Womens Health (Lond)       Date:  2017-09-27

3.  Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer.

Authors:  Jingjing Liu; Jigeun Yoo; Jung Yoon Ho; Yuyeon Jung; Sanha Lee; Soo Young Hur; Youn Jin Choi
Journal:  J Ovarian Res       Date:  2021-04-28       Impact factor: 4.234

4.  Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine.

Authors:  Emily C Kight; Iftak Hussain; Audrey K Bowden; Frederick R Haselton
Journal:  Sci Rep       Date:  2021-11-09       Impact factor: 4.379

5.  Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.

Authors:  Masato Yoshihara; Hiroaki Kajiyama; Akira Yokoi; Mai Sugiyama; Yoshihiro Koya; Yoshihiko Yamakita; Wenting Liu; Kae Nakamura; Yoshinori Moriyama; Hiroaki Yasui; Shiro Suzuki; Yusuke Yamamoto; Carmela Ricciardelli; Akihiro Nawa; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Int J Cancer       Date:  2020-01-24       Impact factor: 7.396
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.